Iain Ross
Presidente en SILENCE THERAPEUTICS PLC .
Fortuna: 197 697 $ al 30/11/2023
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Derek Lindsay | M | 62 |
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | 8 años |
| James Robert Mead | M | 46 | 6 años | |
| Craig Tooman | M | 58 | 3 años | |
| John Friend | M | 54 | 3 años | |
| Megan Boston | F | 52 |
Benitec Biopharma Ltd.
 Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 8 años |
| Ahmad Mortazavi | M | 53 | 4 años | |
| Graham Dick | M | 73 | 9 años | |
| Dominic Nicholas Jackson | M | - |
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | 3 años |
| Frank Beechinor-Collins | M | 60 | 10 años | |
| Peter Presland | M | 75 | 7 años | |
| Michael Kauffman | M | 60 | 2 años | |
| Lisa Anson | F | - | 6 años | |
| Marie Wikström Lindholm | M | - | 7 años | |
| Rhonda L. Hellums | F | 52 | 3 años | |
| Gem Hopkins | M | - | 4 años | |
| Robert Hawkins | M | 69 | 3 años | |
| Elise Brownell | M | - | 10 años | |
| Ebru Davidson | F | - | 1 años | |
| J. Buchi | M | 69 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 11 años |
| Michael Owen | M | 73 | 9 años | |
| Martin Walton | M | 61 | 2 años | |
| William Paris | M | 73 | 3 años | |
| Barbara Staehelin | F | 61 | 3 años | |
| Steven Romano | M | 64 | 5 años | |
| Susan Lowther | F | 65 | 3 años | |
| Michael Bretherton | M | 68 | 4 años | |
| David Lemus | M | 61 | 6 años | |
| Michael Davidson | M | 67 | 3 años | |
| Simon Dew | M | - | 2 años | |
| J.P. Gabriel | M | - | 1 años | |
| Oliver Schon | M | - | 3 años | |
| Giles Moss | M | - | 3 años | |
| Suzanne Hancock | F | - | 7 años | |
| Eric Fink | M | - | 2 años | |
| Karen R. Krumeich | F | 70 | 2 años | |
| Linnea Corwin Elrington | F | - | 7 años | |
| Peter Roelvink | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 9 años |
| Bryan Dulhunty | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 8 años |
| Peter Collum | M | - | 3 años | |
| James Ede-Golightly | M | 44 | 5 años | |
| Simon Dixon | M | - |
Biomer Technology Ltd.
 Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Ian Harris | M | - |
Biomer Technology Ltd.
Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Duncan Fitzwilliams | M | - |
Biomer Technology Ltd.
Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Anna Sandham | F | - | 1 años | |
| Eric Floyd | M | 62 | 5 años | |
| Shaun Stapleton | M | - | 9 años | |
| Paul A. Sherman | M | - | 3 años | |
| Curtis Rambaran | M | - | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Mel Bridges | M | 73 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 11 años |
| John Hawkins | M | 58 | 10 años | |
| David Venables | M | - |
Ark Therapeutics Group Plc
 Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 3 años |
| Gregory West | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 7 años |
| Norman Molyneux | M | 68 | 7 años | |
| Martyn D. Williams | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 14 años |
| Diana Bartlett | F | 62 | 8 años | |
| Mark Rothera | M | 61 | 2 años | |
| Susan MacLeman | F | - | 4 años | |
| Seppo Ylä-Herttuala | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 16 años |
| Catherine Isted | F | - | 2 años | |
| David James Stuart Hetzel | M | - | 4 años | |
| Peter William French | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 6 años |
| Steven Medlicott | M | 59 | 6 años | |
| Cristyn Humphreys | F | - | - | |
| Neil David Murray | M | 60 | 7 años | |
| Brendan Middleton | M | - | 4 años | |
| Tracie Elizabeth Ramsdale | M | 62 | 6 años | |
| Stephen Parker | M | 65 | 6 años | |
| John Paul O'Connor | M | 75 | 5 años | |
| Steven John Mercer | M | - | 11 años | |
| Roger Clarke | M | 76 | 12 años | |
| Timothy Corn | M | 73 | 10 años | |
| Robert Quinn | M | 41 | 4 años | |
| Gabrielle Heaton | F | - | 5 años | |
| Stephen Squire Foster | M | 72 | 2 años | |
| Peter Gunning | M | - | 2 años | |
| Juliet Thompson | F | 57 | 2 años | |
| Barry French | M | - | - | |
| Daniel Smith | M | - | 1 años | |
| Gordon Hirsch | M | - | 1 años | |
| Will Evans | M | - | 2 años | |
| Barbara A. Ruskin | M | - | - | |
| Alistair Gray | M | 75 | 9 años | |
| Ian M. Phillips | M | - | 2 años | |
| Joseph Rubinfeld | M | 91 | 2 años | |
| Olav Hellebø | M | 59 | 8 años | |
| Giles Campion | M | 69 | 4 años | |
| Sean Torquil Nicolson | M | 58 | 10 años | |
| Raymond Barlow | M | 55 | 3 años | |
| Jeremy Curnock-Cook | M | 75 | - | |
| James Garner | M | - | 7 años | |
| Andrew Nicholas Branson | M | - | - | |
| Karl Hård | M | 62 | 1 años | |
| Philip Haworth | M | 68 | 1 años | |
| John W. Rawling | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 5 años |
| Drummond McKenzie | M | - | - | |
| David Prince | M | 73 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 9 años |
| Christine Soden | F | 66 | 3 años | |
| Jeremy Randall | M | 60 | 5 años | |
| John Melvyn Davies | M | 68 | 14 años | |
| David Solomon | M | 63 | 2 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Reino Unido | 70 | 70.00% |
| Australia | 29 | 29.00% |
| Estados Unidos | 2 | 2.00% |
| Suecia | 0 | -.--% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Iain Ross
- Red Personal
